http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 20 Feb 2026 21:40:00 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++4++++++++++OMEROS+CORP+++++++++++++++For%3A+Feb+18++Filed+by%3A+Demopulos+Gregory+A+MD/26037793.html si-local-file:///var/storage/secattach/20260220/26037793.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++OMEROS+CORP+++++++++++++++For%3A+Feb+18++Filed+by%3A+Demopulos+Gregory+A+MD/26037793.html Fri, 20 Feb 2026 21:40:00 -0500 O.00024645 OMER http://www.streetinsider.com/SEC+Filings/Form++4++++++++++OMEROS+CORP+++++++++++++++For%3A+Feb+18++Filed+by%3A+Demopulos+Gregory+A+MD/26037793.html si-local-file:///var/storage/secattach/20260220/26037793.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++OMEROS+CORP+++++++++++++++For%3A+Feb+18++Filed+by%3A+Demopulos+Gregory+A+MD/26037793.html Fri, 20 Feb 2026 21:40:00 -0500 O.00024645 OMER http://www.streetinsider.com/Press+Releases/Omeros+Announces+Successful+Primate+Study+in+OncotoX-AML%E2%84%A2+Drug+Program/26007293.html <p class="bwalignc"> — <i>OncotoX-AML Effectively Ablated Myeloid Progenitor Cells that Give Rise to AML in Cancer Patients </i>— </p> <p> SEATTLE--(BUSINESS WIRE)-- Omeros Corporation (NASDAQ: OMER) today announced the successful completion of its initial study in nonhuman primates evaluating the efficacy and safety of its OncotoX-AML cancer therapeutic platform. Omeros’ OncotoX-AML therapeutic is first targeting acute myeloid leukemia (AML), an aggressive and highly fatal bone marrow and blood cancer. The effectiveness of current AML treatments, such as chemotherapeutics and antibody-drug conjugates, are limited by substantial side effects. Administration of only one course of OncotoX-AML treatment to immunocompetent primates demonstrated the desired http://www.streetinsider.com/Press+Releases/Omeros+Announces+Successful+Primate+Study+in+OncotoX-AML%E2%84%A2+Drug+Program/26007293.html Tue, 17 Feb 2026 08:45:00 -0500 A.02973684 A.30249239 A.31066700 A.42229934 O.00024645 O.00285735 O.01768724 O.22422661 O.29828343 OMER http://www.streetinsider.com/Press+Releases/Omeros+Announces+Successful+Primate+Study+in+OncotoX-AML%E2%84%A2+Drug+Program/26007293.html <p class="bwalignc"> — <i>OncotoX-AML Effectively Ablated Myeloid Progenitor Cells that Give Rise to AML in Cancer Patients </i>— </p> <p> SEATTLE--(BUSINESS WIRE)-- Omeros Corporation (NASDAQ: OMER) today announced the successful completion of its initial study in nonhuman primates evaluating the efficacy and safety of its OncotoX-AML cancer therapeutic platform. Omeros’ OncotoX-AML therapeutic is first targeting acute myeloid leukemia (AML), an aggressive and highly fatal bone marrow and blood cancer. The effectiveness of current AML treatments, such as chemotherapeutics and antibody-drug conjugates, are limited by substantial side effects. Administration of only one course of OncotoX-AML treatment to immunocompetent primates demonstrated the desired http://www.streetinsider.com/Press+Releases/Omeros+Announces+Successful+Primate+Study+in+OncotoX-AML%E2%84%A2+Drug+Program/26007293.html Tue, 17 Feb 2026 08:45:00 -0500 A.02973684 A.30249239 A.31066700 A.42229934 O.00024645 O.00285735 O.01768724 O.22422661 O.29828343 OMER http://www.streetinsider.com/Press+Releases/Omeros+Announces+Successful+Primate+Study+in+OncotoX-AML%E2%84%A2+Drug+Program/26007293.html <p class="bwalignc"> — <i>OncotoX-AML Effectively Ablated Myeloid Progenitor Cells that Give Rise to AML in Cancer Patients </i>— </p> <p> SEATTLE--(BUSINESS WIRE)-- Omeros Corporation (NASDAQ: OMER) today announced the successful completion of its initial study in nonhuman primates evaluating the efficacy and safety of its OncotoX-AML cancer therapeutic platform. Omeros’ OncotoX-AML therapeutic is first targeting acute myeloid leukemia (AML), an aggressive and highly fatal bone marrow and blood cancer. The effectiveness of current AML treatments, such as chemotherapeutics and antibody-drug conjugates, are limited by substantial side effects. Administration of only one course of OncotoX-AML treatment to immunocompetent primates demonstrated the desired http://www.streetinsider.com/Press+Releases/Omeros+Announces+Successful+Primate+Study+in+OncotoX-AML%E2%84%A2+Drug+Program/26007293.html Tue, 17 Feb 2026 08:45:00 -0500 A.02973684 A.30249239 A.31066700 A.42229934 O.00024645 O.00285735 O.01768724 O.22422661 O.29828343 OMER http://www.streetinsider.com/Press+Releases/Omeros+Announces+Successful+Primate+Study+in+OncotoX-AML%E2%84%A2+Drug+Program/26007293.html <p class="bwalignc"> — <i>OncotoX-AML Effectively Ablated Myeloid Progenitor Cells that Give Rise to AML in Cancer Patients </i>— </p> <p> SEATTLE--(BUSINESS WIRE)-- Omeros Corporation (NASDAQ: OMER) today announced the successful completion of its initial study in nonhuman primates evaluating the efficacy and safety of its OncotoX-AML cancer therapeutic platform. Omeros’ OncotoX-AML therapeutic is first targeting acute myeloid leukemia (AML), an aggressive and highly fatal bone marrow and blood cancer. The effectiveness of current AML treatments, such as chemotherapeutics and antibody-drug conjugates, are limited by substantial side effects. Administration of only one course of OncotoX-AML treatment to immunocompetent primates demonstrated the desired http://www.streetinsider.com/Press+Releases/Omeros+Announces+Successful+Primate+Study+in+OncotoX-AML%E2%84%A2+Drug+Program/26007293.html Tue, 17 Feb 2026 08:45:00 -0500 A.02973684 A.30249239 A.31066700 A.42229934 O.00024645 O.00285735 O.01768724 O.22422661 O.29828343 OMER http://www.streetinsider.com/Press+Releases/Omeros+Announces+Successful+Primate+Study+in+OncotoX-AML%E2%84%A2+Drug+Program/26007293.html <p class="bwalignc"> — <i>OncotoX-AML Effectively Ablated Myeloid Progenitor Cells that Give Rise to AML in Cancer Patients </i>— </p> <p> SEATTLE--(BUSINESS WIRE)-- Omeros Corporation (NASDAQ: OMER) today announced the successful completion of its initial study in nonhuman primates evaluating the efficacy and safety of its OncotoX-AML cancer therapeutic platform. Omeros’ OncotoX-AML therapeutic is first targeting acute myeloid leukemia (AML), an aggressive and highly fatal bone marrow and blood cancer. The effectiveness of current AML treatments, such as chemotherapeutics and antibody-drug conjugates, are limited by substantial side effects. Administration of only one course of OncotoX-AML treatment to immunocompetent primates demonstrated the desired http://www.streetinsider.com/Press+Releases/Omeros+Announces+Successful+Primate+Study+in+OncotoX-AML%E2%84%A2+Drug+Program/26007293.html Tue, 17 Feb 2026 08:45:00 -0500 A.02973684 A.30249239 A.31066700 A.42229934 O.00024645 O.00285735 O.01768724 O.22422661 O.29828343 OMER http://www.streetinsider.com/Press+Releases/Omeros+Announces+Successful+Primate+Study+in+OncotoX-AML%E2%84%A2+Drug+Program/26007293.html <p class="bwalignc"> — <i>OncotoX-AML Effectively Ablated Myeloid Progenitor Cells that Give Rise to AML in Cancer Patients </i>— </p> <p> SEATTLE--(BUSINESS WIRE)-- Omeros Corporation (NASDAQ: OMER) today announced the successful completion of its initial study in nonhuman primates evaluating the efficacy and safety of its OncotoX-AML cancer therapeutic platform. Omeros’ OncotoX-AML therapeutic is first targeting acute myeloid leukemia (AML), an aggressive and highly fatal bone marrow and blood cancer. The effectiveness of current AML treatments, such as chemotherapeutics and antibody-drug conjugates, are limited by substantial side effects. Administration of only one course of OncotoX-AML treatment to immunocompetent primates demonstrated the desired http://www.streetinsider.com/Press+Releases/Omeros+Announces+Successful+Primate+Study+in+OncotoX-AML%E2%84%A2+Drug+Program/26007293.html Tue, 17 Feb 2026 08:45:00 -0500 A.02973684 A.30249239 A.31066700 A.42229934 O.00024645 O.00285735 O.01768724 O.22422661 O.29828343 OMER http://www.streetinsider.com/Press+Releases/Omeros+Announces+Successful+Primate+Study+in+OncotoX-AML%E2%84%A2+Drug+Program/26007293.html <p class="bwalignc"> — <i>OncotoX-AML Effectively Ablated Myeloid Progenitor Cells that Give Rise to AML in Cancer Patients </i>— </p> <p> SEATTLE--(BUSINESS WIRE)-- Omeros Corporation (NASDAQ: OMER) today announced the successful completion of its initial study in nonhuman primates evaluating the efficacy and safety of its OncotoX-AML cancer therapeutic platform. Omeros’ OncotoX-AML therapeutic is first targeting acute myeloid leukemia (AML), an aggressive and highly fatal bone marrow and blood cancer. The effectiveness of current AML treatments, such as chemotherapeutics and antibody-drug conjugates, are limited by substantial side effects. Administration of only one course of OncotoX-AML treatment to immunocompetent primates demonstrated the desired http://www.streetinsider.com/Press+Releases/Omeros+Announces+Successful+Primate+Study+in+OncotoX-AML%E2%84%A2+Drug+Program/26007293.html Tue, 17 Feb 2026 08:45:00 -0500 A.02973684 A.30249239 A.31066700 A.42229934 O.00024645 O.00285735 O.01768724 O.22422661 O.29828343 OMER http://www.streetinsider.com/Press+Releases/Omeros+Announces+Successful+Primate+Study+in+OncotoX-AML%E2%84%A2+Drug+Program/26007293.html <p class="bwalignc"> — <i>OncotoX-AML Effectively Ablated Myeloid Progenitor Cells that Give Rise to AML in Cancer Patients </i>— </p> <p> SEATTLE--(BUSINESS WIRE)-- Omeros Corporation (NASDAQ: OMER) today announced the successful completion of its initial study in nonhuman primates evaluating the efficacy and safety of its OncotoX-AML cancer therapeutic platform. Omeros’ OncotoX-AML therapeutic is first targeting acute myeloid leukemia (AML), an aggressive and highly fatal bone marrow and blood cancer. The effectiveness of current AML treatments, such as chemotherapeutics and antibody-drug conjugates, are limited by substantial side effects. Administration of only one course of OncotoX-AML treatment to immunocompetent primates demonstrated the desired http://www.streetinsider.com/Press+Releases/Omeros+Announces+Successful+Primate+Study+in+OncotoX-AML%E2%84%A2+Drug+Program/26007293.html Tue, 17 Feb 2026 08:45:00 -0500 A.02973684 A.30249239 A.31066700 A.42229934 O.00024645 O.00285735 O.01768724 O.22422661 O.29828343 OMER http://www.streetinsider.com/Press+Releases/Omeros+Announces+Successful+Primate+Study+in+OncotoX-AML%E2%84%A2+Drug+Program/26007293.html <p class="bwalignc"> — <i>OncotoX-AML Effectively Ablated Myeloid Progenitor Cells that Give Rise to AML in Cancer Patients </i>— </p> <p> SEATTLE--(BUSINESS WIRE)-- Omeros Corporation (NASDAQ: OMER) today announced the successful completion of its initial study in nonhuman primates evaluating the efficacy and safety of its OncotoX-AML cancer therapeutic platform. Omeros’ OncotoX-AML therapeutic is first targeting acute myeloid leukemia (AML), an aggressive and highly fatal bone marrow and blood cancer. The effectiveness of current AML treatments, such as chemotherapeutics and antibody-drug conjugates, are limited by substantial side effects. Administration of only one course of OncotoX-AML treatment to immunocompetent primates demonstrated the desired http://www.streetinsider.com/Press+Releases/Omeros+Announces+Successful+Primate+Study+in+OncotoX-AML%E2%84%A2+Drug+Program/26007293.html Tue, 17 Feb 2026 08:45:00 -0500 A.02973684 A.30249239 A.31066700 A.42229934 O.00024645 O.00285735 O.01768724 O.22422661 O.29828343 OMER http://www.streetinsider.com/Press+Releases/Omeros+Announces+Successful+Primate+Study+in+OncotoX-AML%E2%84%A2+Drug+Program/26007293.html <p class="bwalignc"> — <i>OncotoX-AML Effectively Ablated Myeloid Progenitor Cells that Give Rise to AML in Cancer Patients </i>— </p> <p> SEATTLE--(BUSINESS WIRE)-- Omeros Corporation (NASDAQ: OMER) today announced the successful completion of its initial study in nonhuman primates evaluating the efficacy and safety of its OncotoX-AML cancer therapeutic platform. Omeros’ OncotoX-AML therapeutic is first targeting acute myeloid leukemia (AML), an aggressive and highly fatal bone marrow and blood cancer. The effectiveness of current AML treatments, such as chemotherapeutics and antibody-drug conjugates, are limited by substantial side effects. Administration of only one course of OncotoX-AML treatment to immunocompetent primates demonstrated the desired http://www.streetinsider.com/Press+Releases/Omeros+Announces+Successful+Primate+Study+in+OncotoX-AML%E2%84%A2+Drug+Program/26007293.html Tue, 17 Feb 2026 08:45:00 -0500 A.02973684 A.30249239 A.31066700 A.42229934 O.00024645 O.00285735 O.01768724 O.22422661 O.29828343 OMER http://www.streetinsider.com/Business+Wire/Omeros+Announces+Successful+Primate+Study+in+OncotoX-AML%E2%84%A2+Drug+Program/26007293.html <p class="bwalignc"> — <i>OncotoX-AML Effectively Ablated Myeloid Progenitor Cells that Give Rise to AML in Cancer Patients </i>— </p> <p> SEATTLE--(BUSINESS WIRE)-- Omeros Corporation (NASDAQ: OMER) today announced the successful completion of its initial study in nonhuman primates evaluating the efficacy and safety of its OncotoX-AML cancer therapeutic platform. Omeros’ OncotoX-AML therapeutic is first targeting acute myeloid leukemia (AML), an aggressive and highly fatal bone marrow and blood cancer. The effectiveness of current AML treatments, such as chemotherapeutics and antibody-drug conjugates, are limited by substantial side effects. Administration of only one course of OncotoX-AML treatment to immunocompetent primates demonstrated the desired http://www.streetinsider.com/Business+Wire/Omeros+Announces+Successful+Primate+Study+in+OncotoX-AML%E2%84%A2+Drug+Program/26007293.html Tue, 17 Feb 2026 08:45:00 -0500 A.02973684 A.30249239 A.31066700 A.42229934 O.00024645 O.00285735 O.01768724 O.22422661 O.29828343 OMER http://www.streetinsider.com/Business+Wire/Omeros+Announces+Successful+Primate+Study+in+OncotoX-AML%E2%84%A2+Drug+Program/26007293.html <p class="bwalignc"> — <i>OncotoX-AML Effectively Ablated Myeloid Progenitor Cells that Give Rise to AML in Cancer Patients </i>— </p> <p> SEATTLE--(BUSINESS WIRE)-- Omeros Corporation (NASDAQ: OMER) today announced the successful completion of its initial study in nonhuman primates evaluating the efficacy and safety of its OncotoX-AML cancer therapeutic platform. Omeros’ OncotoX-AML therapeutic is first targeting acute myeloid leukemia (AML), an aggressive and highly fatal bone marrow and blood cancer. The effectiveness of current AML treatments, such as chemotherapeutics and antibody-drug conjugates, are limited by substantial side effects. Administration of only one course of OncotoX-AML treatment to immunocompetent primates demonstrated the desired http://www.streetinsider.com/Business+Wire/Omeros+Announces+Successful+Primate+Study+in+OncotoX-AML%E2%84%A2+Drug+Program/26007293.html Tue, 17 Feb 2026 08:45:00 -0500 A.02973684 A.30249239 A.31066700 A.42229934 O.00024645 O.00285735 O.01768724 O.22422661 O.29828343 OMER http://www.streetinsider.com/Business+Wire/Omeros+Announces+Successful+Primate+Study+in+OncotoX-AML%E2%84%A2+Drug+Program/26007293.html <p class="bwalignc"> — <i>OncotoX-AML Effectively Ablated Myeloid Progenitor Cells that Give Rise to AML in Cancer Patients </i>— </p> <p> SEATTLE--(BUSINESS WIRE)-- Omeros Corporation (NASDAQ: OMER) today announced the successful completion of its initial study in nonhuman primates evaluating the efficacy and safety of its OncotoX-AML cancer therapeutic platform. Omeros’ OncotoX-AML therapeutic is first targeting acute myeloid leukemia (AML), an aggressive and highly fatal bone marrow and blood cancer. The effectiveness of current AML treatments, such as chemotherapeutics and antibody-drug conjugates, are limited by substantial side effects. Administration of only one course of OncotoX-AML treatment to immunocompetent primates demonstrated the desired http://www.streetinsider.com/Business+Wire/Omeros+Announces+Successful+Primate+Study+in+OncotoX-AML%E2%84%A2+Drug+Program/26007293.html Tue, 17 Feb 2026 08:45:00 -0500 A.02973684 A.30249239 A.31066700 A.42229934 O.00024645 O.00285735 O.01768724 O.22422661 O.29828343 OMER http://www.streetinsider.com/Business+Wire/Omeros+Announces+Successful+Primate+Study+in+OncotoX-AML%E2%84%A2+Drug+Program/26007293.html <p class="bwalignc"> — <i>OncotoX-AML Effectively Ablated Myeloid Progenitor Cells that Give Rise to AML in Cancer Patients </i>— </p> <p> SEATTLE--(BUSINESS WIRE)-- Omeros Corporation (NASDAQ: OMER) today announced the successful completion of its initial study in nonhuman primates evaluating the efficacy and safety of its OncotoX-AML cancer therapeutic platform. Omeros’ OncotoX-AML therapeutic is first targeting acute myeloid leukemia (AML), an aggressive and highly fatal bone marrow and blood cancer. The effectiveness of current AML treatments, such as chemotherapeutics and antibody-drug conjugates, are limited by substantial side effects. Administration of only one course of OncotoX-AML treatment to immunocompetent primates demonstrated the desired http://www.streetinsider.com/Business+Wire/Omeros+Announces+Successful+Primate+Study+in+OncotoX-AML%E2%84%A2+Drug+Program/26007293.html Tue, 17 Feb 2026 08:45:00 -0500 A.02973684 A.30249239 A.31066700 A.42229934 O.00024645 O.00285735 O.01768724 O.22422661 O.29828343 OMER http://www.streetinsider.com/Business+Wire/Omeros+Announces+Successful+Primate+Study+in+OncotoX-AML%E2%84%A2+Drug+Program/26007293.html <p class="bwalignc"> — <i>OncotoX-AML Effectively Ablated Myeloid Progenitor Cells that Give Rise to AML in Cancer Patients </i>— </p> <p> SEATTLE--(BUSINESS WIRE)-- Omeros Corporation (NASDAQ: OMER) today announced the successful completion of its initial study in nonhuman primates evaluating the efficacy and safety of its OncotoX-AML cancer therapeutic platform. Omeros’ OncotoX-AML therapeutic is first targeting acute myeloid leukemia (AML), an aggressive and highly fatal bone marrow and blood cancer. The effectiveness of current AML treatments, such as chemotherapeutics and antibody-drug conjugates, are limited by substantial side effects. Administration of only one course of OncotoX-AML treatment to immunocompetent primates demonstrated the desired http://www.streetinsider.com/Business+Wire/Omeros+Announces+Successful+Primate+Study+in+OncotoX-AML%E2%84%A2+Drug+Program/26007293.html Tue, 17 Feb 2026 08:45:00 -0500 A.02973684 A.30249239 A.31066700 A.42229934 O.00024645 O.00285735 O.01768724 O.22422661 O.29828343 OMER http://www.streetinsider.com/Business+Wire/Omeros+Announces+Successful+Primate+Study+in+OncotoX-AML%E2%84%A2+Drug+Program/26007293.html <p class="bwalignc"> — <i>OncotoX-AML Effectively Ablated Myeloid Progenitor Cells that Give Rise to AML in Cancer Patients </i>— </p> <p> SEATTLE--(BUSINESS WIRE)-- Omeros Corporation (NASDAQ: OMER) today announced the successful completion of its initial study in nonhuman primates evaluating the efficacy and safety of its OncotoX-AML cancer therapeutic platform. Omeros’ OncotoX-AML therapeutic is first targeting acute myeloid leukemia (AML), an aggressive and highly fatal bone marrow and blood cancer. The effectiveness of current AML treatments, such as chemotherapeutics and antibody-drug conjugates, are limited by substantial side effects. Administration of only one course of OncotoX-AML treatment to immunocompetent primates demonstrated the desired http://www.streetinsider.com/Business+Wire/Omeros+Announces+Successful+Primate+Study+in+OncotoX-AML%E2%84%A2+Drug+Program/26007293.html Tue, 17 Feb 2026 08:45:00 -0500 A.02973684 A.30249239 A.31066700 A.42229934 O.00024645 O.00285735 O.01768724 O.22422661 O.29828343 OMER http://www.streetinsider.com/Business+Wire/Omeros+Announces+Successful+Primate+Study+in+OncotoX-AML%E2%84%A2+Drug+Program/26007293.html <p class="bwalignc"> — <i>OncotoX-AML Effectively Ablated Myeloid Progenitor Cells that Give Rise to AML in Cancer Patients </i>— </p> <p> SEATTLE--(BUSINESS WIRE)-- Omeros Corporation (NASDAQ: OMER) today announced the successful completion of its initial study in nonhuman primates evaluating the efficacy and safety of its OncotoX-AML cancer therapeutic platform. Omeros’ OncotoX-AML therapeutic is first targeting acute myeloid leukemia (AML), an aggressive and highly fatal bone marrow and blood cancer. The effectiveness of current AML treatments, such as chemotherapeutics and antibody-drug conjugates, are limited by substantial side effects. Administration of only one course of OncotoX-AML treatment to immunocompetent primates demonstrated the desired http://www.streetinsider.com/Business+Wire/Omeros+Announces+Successful+Primate+Study+in+OncotoX-AML%E2%84%A2+Drug+Program/26007293.html Tue, 17 Feb 2026 08:45:00 -0500 A.02973684 A.30249239 A.31066700 A.42229934 O.00024645 O.00285735 O.01768724 O.22422661 O.29828343 OMER http://www.streetinsider.com/Business+Wire/Omeros+Announces+Successful+Primate+Study+in+OncotoX-AML%E2%84%A2+Drug+Program/26007293.html <p class="bwalignc"> — <i>OncotoX-AML Effectively Ablated Myeloid Progenitor Cells that Give Rise to AML in Cancer Patients </i>— </p> <p> SEATTLE--(BUSINESS WIRE)-- Omeros Corporation (NASDAQ: OMER) today announced the successful completion of its initial study in nonhuman primates evaluating the efficacy and safety of its OncotoX-AML cancer therapeutic platform. Omeros’ OncotoX-AML therapeutic is first targeting acute myeloid leukemia (AML), an aggressive and highly fatal bone marrow and blood cancer. The effectiveness of current AML treatments, such as chemotherapeutics and antibody-drug conjugates, are limited by substantial side effects. Administration of only one course of OncotoX-AML treatment to immunocompetent primates demonstrated the desired http://www.streetinsider.com/Business+Wire/Omeros+Announces+Successful+Primate+Study+in+OncotoX-AML%E2%84%A2+Drug+Program/26007293.html Tue, 17 Feb 2026 08:45:00 -0500 A.02973684 A.30249239 A.31066700 A.42229934 O.00024645 O.00285735 O.01768724 O.22422661 O.29828343 OMER http://www.streetinsider.com/Business+Wire/Omeros+Announces+Successful+Primate+Study+in+OncotoX-AML%E2%84%A2+Drug+Program/26007293.html <p class="bwalignc"> — <i>OncotoX-AML Effectively Ablated Myeloid Progenitor Cells that Give Rise to AML in Cancer Patients </i>— </p> <p> SEATTLE--(BUSINESS WIRE)-- Omeros Corporation (NASDAQ: OMER) today announced the successful completion of its initial study in nonhuman primates evaluating the efficacy and safety of its OncotoX-AML cancer therapeutic platform. Omeros’ OncotoX-AML therapeutic is first targeting acute myeloid leukemia (AML), an aggressive and highly fatal bone marrow and blood cancer. The effectiveness of current AML treatments, such as chemotherapeutics and antibody-drug conjugates, are limited by substantial side effects. Administration of only one course of OncotoX-AML treatment to immunocompetent primates demonstrated the desired http://www.streetinsider.com/Business+Wire/Omeros+Announces+Successful+Primate+Study+in+OncotoX-AML%E2%84%A2+Drug+Program/26007293.html Tue, 17 Feb 2026 08:45:00 -0500 A.02973684 A.30249239 A.31066700 A.42229934 O.00024645 O.00285735 O.01768724 O.22422661 O.29828343 OMER http://www.streetinsider.com/Business+Wire/Omeros+Announces+Successful+Primate+Study+in+OncotoX-AML%E2%84%A2+Drug+Program/26007293.html <p class="bwalignc"> — <i>OncotoX-AML Effectively Ablated Myeloid Progenitor Cells that Give Rise to AML in Cancer Patients </i>— </p> <p> SEATTLE--(BUSINESS WIRE)-- Omeros Corporation (NASDAQ: OMER) today announced the successful completion of its initial study in nonhuman primates evaluating the efficacy and safety of its OncotoX-AML cancer therapeutic platform. Omeros’ OncotoX-AML therapeutic is first targeting acute myeloid leukemia (AML), an aggressive and highly fatal bone marrow and blood cancer. The effectiveness of current AML treatments, such as chemotherapeutics and antibody-drug conjugates, are limited by substantial side effects. Administration of only one course of OncotoX-AML treatment to immunocompetent primates demonstrated the desired http://www.streetinsider.com/Business+Wire/Omeros+Announces+Successful+Primate+Study+in+OncotoX-AML%E2%84%A2+Drug+Program/26007293.html Tue, 17 Feb 2026 08:45:00 -0500 A.02973684 A.30249239 A.31066700 A.42229934 O.00024645 O.00285735 O.01768724 O.22422661 O.29828343 OMER http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++OMEROS+CORP++++++++++++++++++++++++++++Filed+by%3A+VANGUARD+GROUP+INC/25922589.html si-local-file:///var/storage/secattach/20260130/25922589.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++OMEROS+CORP++++++++++++++++++++++++++++Filed+by%3A+VANGUARD+GROUP+INC/25922589.html Fri, 30 Jan 2026 14:20:00 -0500 O.00024645 OMER http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++OMEROS+CORP++++++++++++++++++++++++++++Filed+by%3A+VANGUARD+GROUP+INC/25922589.html si-local-file:///var/storage/secattach/20260130/25922589.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++OMEROS+CORP++++++++++++++++++++++++++++Filed+by%3A+VANGUARD+GROUP+INC/25922589.html Fri, 30 Jan 2026 14:20:00 -0500 O.00024645 OMER http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++OMEROS+CORP++++++++++++++++++++++++++++Filed+by%3A+VANGUARD+GROUP+INC/25922590.html si-local-file:///var/storage/secattach/20260130/25922590.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++OMEROS+CORP++++++++++++++++++++++++++++Filed+by%3A+VANGUARD+GROUP+INC/25922590.html Fri, 30 Jan 2026 14:20:00 -0500 O.00024645 OMER